<DOC>
	<DOC>NCT00617474</DOC>
	<brief_summary>The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.</brief_summary>
	<brief_title>The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Hb: &gt;8 and &lt;10 gr/dl Age: &gt;18 and &lt;55 years Cholesterol: &lt;300 mg/dl Triglyceride: &lt;400 mg/dl First Transplantation Protocol of Immunosuppression: CSA + MMF + Prednisolone Systolic BP: &lt;14 Diastolic BP: &lt;9 History of specified cardiac disease Second Transplantation or more Hb: &lt;7gr/dl The patient needs to infusion of blood Evidence of local or systemic infection, at the time of EPO injection Presence of ATN / DGF after transplantation Presence of emergent hypertension High risk patients ( Like; PRA&gt;50%) Past history of hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>erythropoietin</keyword>
	<keyword>kidney allograft survival</keyword>
	<keyword>Recombinant Erythropoietin</keyword>
	<keyword>erythropoietin (Epo)-induced protein 29, human</keyword>
</DOC>